Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68773 | 0.69 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL33371399 | 0.69 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL12473611 | 0.67 | CRBN (0.32) | CRBNDDB1 | |
| SCHEMBL2974249 | 0.67 | CRBN (0.32) | CRBNDDB1IKZF3 | |
| SCHEMBL7099066 | 0.64 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL4432323 | 0.62 | — | — | |
| SCHEMBL9731788 | 0.62 | MAPT (0.34) | CRBNDDB1 | |
| SCHEMBL350287 | 0.62 | — | — | |
| SCHEMBL15703044 | 0.61 | DDB1 (0.36) | CRBNDDB1 | |
| SCHEMBL6232358 | 0.61 | CRBN (0.33) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-6265406-B1 | VIRICIDES | DUPONT PHARMACEUTICALS COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6090821-A | ENZYME INHIBITORS; VIRICIDES | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | CRBN 4370/4885DDB1 4521/4885IKZF3 2945/4885 |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | CRBN 4370/4885DDB1 4521/4885IKZF3 2945/4885 |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | CRBN 4370/4885DDB1 4521/4885IKZF3 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.